Fear of monkeypox and intention to vaccinate against monkeypox: a network analysis
Miedo a la viruela del mono y la intención de vacunarse contra la viruela del mono: un análisis de redes

Tomás Caycho-Rodriguez, José Ventura-León, Carlos Carbajal-León, Lindsey W. Vilca, Miguel Gallegos, Mariel Delgado-Campusano, Martin Noe-Grijalva, Águeda Muñoz-del-Carpio-Toia, Nicol A. Barria-Asenjo, Julio Torales, Luis Hualparuca-Olivera, Jesús Ayala-Colqui, Mario Reyes-Bossio

ABSTRACT
Introduction: The presence of fear of an infectious disease triggers psychological factors associated with perceived behavioral control over vaccination acceptance, subjective norms of vaccination acceptance, attitudes toward vaccination acceptance, and perceived infectiousness from disease. Objective: The study evaluated how symptoms of fear of Monkeypox specifically relate to intention to be vaccinated against Monkeypox in a sample of 506 Peruvian individuals with a mean age of 27.11 years (SD = 9.77). Methods: Participants responded to the Monkeypox Fear Scale (MFS) and a single item of Intention to be vaccinated against Monkeypox. Using network analysis, central fear symptoms and associations between symptoms and intention to vaccinate were identified. Results: The results suggest that the node with the highest centrality was item 5 of the MFS. Regarding the connection between the intention to be vaccinated and the MFS items, a direct relationship was observed with item 1 and an inverse relationship with item 6. In addition, the relationship between these MFS items and intention to vaccinate is higher in men compared to women. While it would be expected that a greater presence of symptoms of fear of Monkeypox could lead people to have a greater intention to be vaccinated against the disease, the results could lead other researchers to generate evidence to explain this relationship in other Latin American countries. Discussion: The evidence is useful for developing policies that favor vaccination against Monkeypox in Peru and other Latin American countries.

Keywords: monkeypox; fear; networks; vaccination.

RESUMEN
Introducción: La presencia del miedo a una enfermedad infecciosa desencadena factores psicológicos asociados con el control conductual percibido sobre la aceptación de la vacunación, normas subjetivas de aceptación de la vacunación, actitudes hacia la aceptación de la vacunación y la percepción de la Infectividad de la enfermedad. Objetivo: El estudio evaluó cómo los síntomas del miedo a la viruela del mono se relacionan específicamente con la intención de ser vacunado contra la viruela del mono en una muestra de 506 individuos peruanos con una edad promedio de 27.11 años (DE = 9.77). Métodos: Los participantes respondieron a la Escala de Miedo a la Viruela del Mono (MFS) y a un solo ítem de Intención de ser vacunado contra la viruela del mono. Utilizando análisis de redes, se identificaron los síntomas centrales del miedo y las asociaciones entre los síntomas y la intención de vacunarse. Resultados: Los resultados sugieren que el nodo con mayor centralidad fue el ítem 5 de la MFS. En cuanto a la conexión entre la intención de ser vacunado y los ítems de la MFS, se observó una relación directa con el ítem 1 y una relación inversa con el ítem 6. Además, la relación entre estos ítems de la MFS y la intención de vacunarse es mayor en hombres en comparación con mujeres. Si bien se esperaría que una mayor presencia de síntomas de miedo a la viruela del mono llevara a las personas a tener una mayor intención de ser vacunadas contra la enfermedad, los resultados podrían llevar a otros investigadores a generar evidencia para explicar esta relación en otros países de América Latina. Discusión: La evidencia es útil para desarrollar políticas que favorezcan la vacunación contra la viruela del mono en Perú y otros países de América Latina.

Palabras clave: viruela del mono; miedo; redes; vacunación.

INTRODUCTION

The COVID-19 pandemic has caused a strong pressure on the health systems of different countries, which has had an impact on the increase of emerging or re-emerging infectious diseases, as is the case of Monkeypox (1). Monkeypox is a zoonotic disease caused by the Monkeypox virus, a type of orthopoxvirus that belongs to the same family as variola, which causes smallpox (2). Symptoms include maculopapular rashes, mainly on the hands and feet, headache, swollen lymph nodes, fever, chills, and myalgia (3). While clinically Monkeypox has less severity than smallpox (4), its mortality rate varies around 3% to 6% (5). After 39 years without the disease being diagnosed in humans, an outbreak of 118 cases of Monkeypox was identified in Nigeria during 2017 and 2018 (6). In early May 2022, a new outbreak of Monkeypox was identified in several countries in Europe, North America, and Australia, where the disease is not endemic (7). Prior to this outbreak, cases of Monkeypox were uncommon outside endemic countries in central and west Africa (8). In response, WHO declared Monkeypox a Public Health Emergency of International Concern (PHEIC) on July 23. As of September 28, 2022, more than 67,000 confirmed cases of Monkeypox have been reported worldwide and 27 deaths from the disease, with numbers continuing to rise (9) (Figure 1). In South America, also as of September 28, 2022, 13,495 diagnosed cases of Monkeypox and 3 deaths from the disease were reported. In this region, Brazil (n= 7534 cases), Peru (n= 2436 cases) and Colombia (n= 2042 cases) were the countries with the highest number of reported cases (Figure 2).

FIGURE 1. MONKEYPOX: ACCUMULATED CONFIRMED CASES WORLDWIDE, SEP 28, 2022. BASED ON DATA FROM OUR WORLD IN DATA.

FIGURE 2. MONKEYPOX: ACCUMULATED CONFIRMED CASES IN SOUTH AMERICA, SEP 28, 2022. BASED ON DATA FROM OUR WORLD IN DATA.
One of the strategies to control the current Monkeypox outbreak is the vaccination of the population against the disease, which is being carried out in some countries in Europe, the USA and Canada (10). In these countries, a "ring vaccination" is being carried out with vaccines against smallpox, which are effective against Monkeypox due to the relationship between the viruses of both diseases (10). Indeed, it has been reported that smallpox vaccines can provide cross-protection (immunity to one disease provides immunity to the other) against Monkeypox in 85% of cases (11). Currently, cidofovir, brincidofovir (CMX001), tecovirimat (ST-246) and immunoglobulin vaccinia (VIG) and JYNNEOS™ (Imvamune or Imvanex) are administered, while the live vaccine ACAM2000 is under trial testing (12). Therefore, there would be a higher incidence rate of Monkeypox among unvaccinated people (13). Information on the efficacy of the vaccines used against Monkeypox is obtained from in vitro, animal studies and clinical trials demonstrating their immunogenicity in humans. However, current vaccines are not specific for the virus causing Monkeypox; moreover, their efficacy on the recent outbreak has not been fully confirmed (10).

The current COVID-19 pandemic has emphasized the importance of worldwide vaccination to protect people against emerging and/or re-emerging infectious diseases, such as Monkeypox. The success of any vaccination program will depend on the acceptance of the population to be vaccinated. However, convincing the population to accept vaccination remains a major challenge and one of the top ten threats to global public health. Intention to vaccinate involves willingness and acceptability to vaccine, as well as positive attitudes toward the vaccine administered, as opposed to resistance or refusal to vaccine (14). A recent survey of health care workers indicated that 55.4% were likely to receive the Monkeypox vaccine and 79% would accept it if it were recommended to the general population (15). Another study with a U.S. sample indicated that 46% would receive a Monkeypox vaccine if it were recommended to them, 29% would refuse to receive it, while 25% were hesitant (16). Finally, another study conducted in the Netherlands indicated that 72% had a high intention to be vaccinated (17). The above data would indicate the presence of a significant percentage of people who would refuse or hesitate to be vaccinated against Monkeypox. As in the COVID-19 pandemic, this would threaten collective immunity against the disease (18). In Peru, it has been reported that Monkeypox vaccines are expected to arrive at the end of September. In this sense, together with the arrival of the Monkeypox vaccine, efforts should also focus on its acceptance to achieve immunity of the entire population.

There are different factors associated with the intention to vaccinate. Previous studies have shown that emotional factors, and in particular fear of disease, significantly influence the way people behave in the face of vaccination campaigns (19). It has been indicated that fear, rather than cognitive risk assessments, drive health behaviors (20). Specifically, it has been suggested that fear of an infectious disease is positively related to vaccination intentions (19, 21, 22). It appears that people with higher levels of fear perceive disease as a threat to their health or those of their loved ones. Therefore, these people would be more willing to get vaccinated to protect themselves and their loved ones against disease. This is important considering that about 62% of the general population reported being more concerned about Monkeypox than COVID-19 (23). Although Monkeypox has a low overall mortality rate, there are aspects that have generated concern and fear, such as the similarity with the smallpox virus, the high number of reported cases, the lack of direct relationship between outbreaks and travel from endemic regions, the lack of clarity about human transmission of the virus, the rapid geographical spread, the lack of data on the effectiveness of available antivirals in treatment, among others (24,25). It has been suggested that the presence of fear of an infectious disease triggers psychological factors associated with perceived behavioral control over vaccination acceptance, subjective norms of vaccination acceptance, attitudes toward vaccination acceptance, and perceived infectiousness from disease (26).

Based on the above, the current study assessed how intention to be vaccinated against Monkeypox specifically relates to symptoms of Monkeypox fear in a sample of Peruvian citizens using network analysis. Specifically, we aim to (a) identify the interrelationship between the nodes of both variables; (b) identify the main nodes in each variable; and (c) compare the networks according to sex, which will allow us to identify whether the networks are invariant and the level of connection at which the networks can be considered almost identical. Network analysis is useful for visualizing the interaction between elements of a network, including symptoms of a syndrome or patterns of behaviors (27). This type of analysis is based on the hypothesis that symptoms or nodes are interdependent and that a mental health problem is made up of a network of symptoms that interact with each other (28, 29). The relationships between the
nodes or symptoms are the edges. Statistically significant edges would not indicate that the symptoms are influenced by underlying latent variables; rather, the symptoms directly influence each other (30). If symptoms interact with each other, some variation in a central symptom will generate changes in other symptoms. However, it should be kept in mind that, in cross-sectional designs, network analyses suggest, but do not determine causality. Although, as mentioned, the presence of significant edges suggests causal influences, experimental designs are necessary to determine causality. Therefore, performing a network analysis provides information to support causal hypotheses between variables within a network. Network analysis has been used to understand the relationship between different variables associated with mental health during the COVID-19 pandemic, both in Peru and other Latin American countries (31,32,33). However, as far as is known from the literature, this technique has not been used to assess mental health symptoms and health behaviors during the Monkeypox public health emergency in any Latin American country. The importance of the study lies in the fact that the identification of symptoms or central nodes, which is characteristic of a network, would allow to identify which nodes to target during clinical intervention (34).

**METHODOLOGY**

**Participants**

There were 506 participants with an average age of 27.11 years (SD = 9.77); 192 males (37.20 %) and 324 females (62.80 %), selected by snowball convenience sampling. Of the participants, 81.2% were married, 8.7% were single, 7% were divorced, 2.3% were widowed, and 0.8% were living with a partner. Likewise, the majority (49.1%) were unemployed at the time of answering the survey, 32.8% had a permanent job, 23.4% had a temporary job and 3.7% were retired. Regarding educational level, 38.2% had incomplete primary education, 28.9% had completed primary education, 20.5% had completed university studies, 8.3% had completed secondary education, 2.1% had incomplete university studies, 1.6% had incomplete secondary education, while 0.4% had incomplete technical studies. Only two people (0.4%) reported having been infected with Monkeypox and 12 reported knowing someone infected with the disease (2.3%). Regarding previous vaccination against COVID-19, 98.8% reported having been vaccinated against the disease. Of those vaccinated, 85.8% indicated that they had received full doses of vaccine, plus booster doses.

The sample was estimated a priori using the ‘netSimulator’ function (35) by varying the sample size between 100, 250, 500, 1000; resulting those 250 data achieved a correlation between the true and estimated networks above 0.80 for the network weights; then, the study exceeded the minimum necessary to perform network analysis. The selection method was non-probabilistic and purposive.

**Instruments**

**Fear of Monkeypox**

The Monkeypox Fear Scale (MFS (36)) was used to measure symptoms of fear of the Monkeypox. The MFS is composed of seven items grouped into two factors: emotional and physiological reactions to Monkeypox fear. Each item presents five Likert-type response options ranging from 1 = strongly disagree to 5 = strongly agree (Appendix 1). A total score for each of the two factors can be obtained from the sum of the scores of the component items. Thus, a higher score would indicate a presence of emotional and physiological reactions to the fear of Monkeypox. In the present study, the reliability estimates for the factors emotional reactions (\(\omega = 0.83\)) and physiological reactions (\(\omega = 0.89\)) are high.

**Intention to be vaccinated against Monkeypox.**

The following single question was used: "How likely are you to receive a Monkeypox vaccine when it becomes available?" constructed ad hoc for this study. Participants answered the question on a five-point scale: 1 = very unlikely; 2 = somewhat unlikely, 3 = unsure, 4 = somewhat likely, 5 = very likely. A higher score indicates a greater intention to vaccinate against Monkeypox. A continuous scale was used, and responses were not grouped as acceptance, hesitancy, or resistance, as this allows for a more accurate understanding of intention to vaccinate. Grouping participants who indicate any response between "somewhat unlikely" and "somewhat likely" could reduce the unique variation to be assessed.

**Procedure**

This cross-sectional study was conducted in Lima between August 21 and September 10, 2022. An online questionnaire containing sociodemographic questions, the MFS, and the single question of intention to be vaccinated against Monkeypox was constructed using the Google Form. The online questionnaire was shared through different online platforms (e.g., WhatsApp, Facebook, Instagram) and email. The study was part of an international project on mental health in a post-pandemic period that involved different Latin American countries, including Peru. This project was...
reviewed and approved by the Institutional Committee for the Protection of Human Subjects in Research (CIPSHI) of the University of Puerto Rico (No. 2223-006). All participants gave their informed consent electronically before answering the questions in the online questionnaire. The anonymity of the participants and the confidentiality of the data were assured, as well as respecting their right to withdraw from the research at any time.

**Data Analysis**

Data analysis was performed with the R programming language in its RStudio environment. The analysis was performed with the psychological network model (30). The sequence of the analysis had as reference what was proposed by Fried et al. (37) performing the estimation, stability, and accuracy of the network.

Estimation was performed with the ggmModSelect function, and a Spearman correlation matrix given the ordinal nature of the data (38). Centrality was performed using Strength which has been shown to be the most stable (39). Other typical measures of centrality such as betweenness and closeness were not used because they present difficulties of interpretation in the field of psychology (40) and empirically they are very unstable (39).

Accuracy and stability were examined through resampling techniques with the 'bootnet' library.

Accuracy consisted of estimating a model several times with the data and calculating a value for the edges. That allowed generating 95% confidence intervals whose width indicates accuracy (Epskamp et al., 2018).

Stability was obtained by a procedure where cases are eliminated until 30% of the data is left and the relationship between true centrality and the resampled values is tested. The resulting value is captured in a coefficient called CS, which can be between $0.25 \leq CS \leq 0.50$ (41).

The comparison was according to sex using the 'NetworkComparisonTest' library (NCT) (42). The NCT uses a permutation procedure in which group differences are examined using 1000 randomly obtained replicates and its null hypothesis is that both groups are equal.

**RESULTS**

Figure 3 shows the response rates for each of the items. It is observed that the item of intention to vaccinate against monkeypox (IV) has a tendency towards high scores. In the case of the scale fear of monkeypox, items 1 and 2 have a predilection for alternative 3 (“Neither agree nor disagree”); while the rest of the items have a tendency towards low scores (“Strongly disagree”).

![FIGURE 3. PRELIMINARY ANALYSIS OF ITEMS](image)

**Network estimation and centrality.**

In the case of the IV item, it is observed that it is close to the items of the Emotional dimension of the fear of Monkeypox. It is evident that the edges are in the range of -.12 to .53 and that 15 of 28 edges are different from zero (53.57% density). The edges within each community were positive. Regarding the connection between IV and the items of the monkeypox fear scale, a direct relationship is observed with MM1 (“Am I very afraid of monkeypox?”) and an
inverse relationship with MM6 ("How likely is it that I will receive a monkeypox vaccine when it becomes available?"). There is no relationship in the rest of the items. In relation to the centrality indexes, item MM5 is the most influential in both Strength and Expected Influence (Figure 4).

**FIGURE 4. NETWORK ESTIMATION AND CENTRALITY INDICES**

Network stability and accuracy
In relation to the stability, it is observed in Figure 5 that the fall of the lines are minimal. This reveals a stability in the centrality indices; likewise, the CS reveal 0.67 and 0.75 for Strength and Expected Influence respectively. Regarding accuracy, it is observed that the difference between the true network (red line) and the estimated network (black line) is small. In addition, the width of the 95% confidence intervals (gray band) are small.

**FIGURE 5. NETWORK STABILITY AND ACCURACY**
Comparison

Broadly speaking, the networks are invariant (M = 0.33; p = .170) and connectivity does not differ (S = .12; p = .59). Likewise, the edges are related (rs = .79). However, a careful analysis shows that the relationship between IV-MM6 and IV-MM1 is higher in males than in females. Finally, the most influential node in both groups is MM5 for both Strength and Expected Influence (Figure 6).

**FIGURE 6. NETWORKS ACCORDING TO GENDER**

**DISCUSSION**

To the best of our knowledge from the scientific literature, this is the first study that evaluated the relationship between symptoms of fear of Monkeypox and intention to be vaccinated against Monkeypox based on a network analysis in a sample of the general population of Peru.

First, although this study did not seek to assess the prevalence of intention to vaccinate, it was observed that there is a trend toward high scores on the item of intention to vaccinate against Monkeypox. That is, most people indicated a high probability of being vaccinated against Monkeypox. This agrees with what has been reported in other studies conducted in different cultural contexts where between 46% and 72% of participants were likely to agree to be vaccinated against Monkeypox (15-17). One of the factors that may have contributed to this result is that most of the participants had previously been vaccinated against COVID-19. It has been suggested that having received previous vaccinations is a predictive factor for vaccination against new diseases (43). However, while intention is an important predictor of acceptance of health behaviors (44), it has been suggested that intention to vaccinate is greater than actual acceptance of the vaccine (45). Therefore, it is important to evaluate the factors associated with the intention to be vaccinated against Monkeypox. On the other hand, items referring to physiological and emotional reactions to fear of Monkeypox presented a tendency to low scores and expressed uncertainty regarding the presence of symptoms. Studies during previous infectious diseases suggested that the threat of infection posed by viruses can generate fear (46,47). However, it is possible that the experience of the previous COVID-19 pandemic and the vaccination strategy implemented in is a possible reason for the low levels of fear experience of this new infectious outbreak in the Peruvian sample.

Fear is a normal response in infectious disease situations that minimizes people’s engagement in risky behaviors and can promote responses that mitigate viruses (48,49). In this sense, the results suggested that the emotional symptoms of fear were found to be closer to the intention to be vaccinated against Monkeypox. This may be expected since, during previous infectious diseases, a greater presence of emotional fear reactions has been observed in the Latin American population rather than physiological...
It has been suggested that physiological symptoms are more characteristic of severe degrees of fear (51). The findings would allow researchers and health professionals to distinguish between fear and its symptoms more closely associated with the intention to be vaccinated against Monkeypox. Specifically, it was observed that the strongest and most direct relationship occurred between intention to vaccinate and the item directly referring to fear of Monkeypox (I am very afraid of monkeypox). From the protection motivation theory, it has been indicated that fear triggers a perception of vulnerability, defined as the perception that a person has of possibly becoming infected, which results in an intention to protect oneself, such as the acceptance of being vaccinated against a disease, in this case Monkeypox (52,53). Another study showed a mechanism that attempts to explain the association between fear of an infectious disease and intention to vaccinate, where psychological factors of perceived behavioral control contribute to people's intentions to vaccinate against the disease (26). On the other hand, the intention to be vaccinated against Monkeypox was inversely associated with the item “I can't sleep because I worry about getting monkeypox”. That is, the presence of sleep problems would decrease the intention to vaccinate. In periods of previous infectious diseases, sleep problems caused by worry about being infected are clinically relevant indicators for the development of fear of the disease in Latin American countries (50). This finding can be explained by the Terror Management Health Model (54), where people who experience fearful states, which generate sleep problems, can cope with proximal, direct, and rational defenses that eliminate the dangerous stimulus, in this case the Monkeypox vaccination.

The relationships between the intention to be vaccinated against Monkeypox and the two fear symptoms mentioned are higher in the male group compared to the female group. This is in line with what has been reported in Peru, where men are one of the groups most at risk of infection. According to the Monkeypox Situation Room of the Ministry of Health, 98.1% of the confirmed cases of Monkeypox occurred in men (55). In this sense, the fact that men are more likely to be infected and experience adverse health consequences from Monkeypox could generate a greater perception of risk and fear, which would predict compliance with preventive measures, such as vaccination against an infectious disease (56,57). Like other studies, this finding would suggest that it is fear of infectious disease, not gender per se, that would generate differences in preventive behavior (58). In addition, these gender differences may reflect state-dependent changes rather than stable personality traits (59,60). These results suggest that communication strategies about Monkeypox and the vaccination process against the disease may have a differential impact according to gender and should consider these differences.

On the other hand, the symptom "When I see news and stories about monkeypox on social networks, I get nervous or anxious" is the most central and influential symptom within the Monkeypox fear symptom network. That this symptom is the most central and influential has also been observed in a previous study on fear of COVID-19 where four South American countries participated, including Peru, (50) participated and in other studies conducted in the Netherlands, Iran, Bangladesh, and Norway during the same pandemic (61,62). Thus, this symptom would be characteristic of periods of infectious disease and could trigger or maintain the other symptoms of Monkeypox fear. It has been suggested that concerns about infectious diseases are related to the compulsive search for verification of information (63). In this sense, the large amount of real-time information about the disease, in many cases erroneous, would generate more fear about its consequences (64,65). The unlimited exchange of information through different media is a constant public health concern (66). A recent study indicated that 52% of tweets about Monkeypox were misinformation or unverifiable information, another 20% were humorous information, and only 28% were serious information about the disease; furthermore, the most frequent misinformation was that the current Monkeypox outbreak is not real and is part of a series of conspiracies (67). The exchange of misinformation can result in stigmatization of the most at-risk groups (68). Although respondents seem to be more complacent about the imminent outbreak of Monkeypox in Peru, policy makers and public health professionals should support greater awareness and sensitization of Monkeypox (69).

It is important to recognize several limitations of this study. First, the cross-sectional design of the study would not allow us to infer causal relationships and variations between fear of Monkeypox and intention to be vaccinated against Monkeypox over time. The symptom networks of Monkeypox fear and intentions to be vaccinated against Monkeypox may change over time and disease progression within a group of people. Second, the generalizability of the findings may be limited to Peruvian participants during a particular phase of the Monkeypox public health emergency of international concern. Data collected during a different period may generate other network structures among
Despite the limitations, the findings may encourage researchers and health professionals to consider the importance of individual symptoms of fear of Monkeypox and their relationships to intentions to vaccinate against the disease. Also, the study has important implications for treatment. In this regard, the presence of highly consistent and reliable core symptoms, as well as stable connections between Monkeypox fear networks and intention to be vaccinated against Monkeypox in groups of men and women, highlighted the importance of long-term monitoring of Monkeypox-associated mental health. There is also potential utility in addressing specific symptoms of Monkeypox fear in interventions designed for the general population of Peru. In this sense, it would be possible to prevent the presence of these symptoms among people who do not intend to be vaccinated against Monkeypox and to treat those who currently suffer concurrent Monkeypox fear symptoms. This would challenge the idea that all Monkeypox fear symptoms have the same impact on the intention to be vaccinated against it. Identifying that the symptom "When I see news and stories about monkeypox on social media, I get nervous or anxious" is the most central, would justify the development of interventions that provide accurate and reliable information about the disease and vaccination through social media, with the aim of combating infodemia and misinformation about the current Monkeypox outbreak. This effort would involve collaboration between public health institutions, health leaders, and social media influencers to promote Monkeypox awareness. Also, there is a need to continuously review social networks, through an alert system, to identify evolving information, the emergence of new rumors and sources of erroneous (70).

In conclusion, this study is the first to identify core symptoms and mediating symptoms within the Monkeypox fear network - the intention to be vaccinated against Monkeypox in a sample of Peruvians. The findings may be useful to future studies evaluating these symptom networks in other countries to better understand the key symptoms that occur among people from different cultures and those symptoms that only occur in specific groups.

AUTHORS CONTRIBUTIONS

TC-R, and JV-L, Conceived and designed the experiments; Analyzed and interpreted the data. CC-L, LWV, MG, MR-B, MN-G, MD-C, ÁM-d-C-T, NAB-A, JT, LH-O, JA-C and CHG-C contributed materials, analysis tools or data; Wrote the paper.

AFFILIATIONS

1 Universidad Científica del Sur, Facultad de Psicología, Grupo de Investigación Métodos cuantitativos e instrumentos para la investigación en ciencias del comportamiento, Lima, Perú.
2 Universidad Privada del Norte, Facultad de Ciencias de la Salud, Lima, Perú.
3 Universidad de San Martín de Porres, Facultad de Ciencias de la Comunicación, Turismo y Psicología, Escuela de Psicología, Lima, Perú.
4 Universidad Norbert Wiener, South American Center for Education and Research in Public Health, Lima, Perú.
5 Universidad Católica del Maule, Facultad de Ciencias de la Salud, Departamento de Psicología, Talca, Chile.
6 Pontificia Universidad Católica de Minas Gerais, Brasil.
7 Universidad Nacional de Rosario, Facultad de Psicología, Rosario, Argentina.
8 Consejo Nacional de Investigaciones Científicas y Técnicas, Argentina.
9 Universidad Peruana de Ciencias Aplicadas, Facultad de Psicología, Lima, Perú.
10 Universidad César Vallejo, Escuela de Psicología, Trujillo, Perú.
11 Universidad Católica de Santa María, Escuela de Medicina Humana, Escuela de Postgrado, Arequipa, Perú.
12 Universidad de Los Lagos, Departamento de Ciencias Sociales, Osorno, Chile.
13 Universidad Nacional de Asunción, Facultad de Ciencias Médicas, Cátedra de Psicología Médica, San Lorenzo, Paraguay.
14 Universidad Sudamericana, Facultad de Ciencias de la Salud, Pedro Juan Caballero, Paraguay.
15 Universidad Continental, Escuela de Psicología, Huancayo, Perú.
16 Universidad Tecnológica del Perú, Lima, Perú.

REFERENCIAS


Med. clín. soc. 2024;8(2):186-197


55. Ministerio de Salud. Sala Situacional de la Viruela del Mono. URL


